Eden Research ( (GB:EDEN) ) has issued an announcement.
Eden Research plc announced that its Non-Executive Chairman, Lykele van der Broek, has purchased 256,000 ordinary shares in the company, increasing his total shareholding to 1,877,808 shares. This purchase underscores confidence in Eden’s strategic direction and its commitment to sustainability in the biopesticide industry, which may positively influence investor perceptions and strengthen the company’s market position.
More about Eden Research
Eden Research plc is a UK-listed company focused on sustainable agriculture through biopesticide and biocontrol technology. It develops and supplies innovative biopesticide products and natural microencapsulation technologies for global crop protection, animal health, and consumer products industries. Its products are based on terpene active ingredients, targeting high-value fruits and vegetables, with a focus on improving crop yields and marketability. Eden’s product lineup includes Mevalone, Novellus, Cedroz, and Ecovelex, which are designed to enhance crop protection and address specific agricultural challenges. The company is committed to sustainability, with 100% of its revenues derived from green economy products.
YTD Price Performance: -3.80%
Average Trading Volume: 739,054
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £20.27M
See more insights into EDEN stock on TipRanks’ Stock Analysis page.